RTN4 and myeloid sarcoma: Given that changes in the levels of Nogo-A and its corresponding receptors, such as Lotus-1, may reflect the development and even progression of MS or ALS, their potential usefulness as new biomarkers for early diagnosis and prognosis of these disorders is indicated.